CYP2D6 and CYP2C19 Polymorphism

CYP2D6 and CYP2C19 polymorphism encompasses the inherited single-nucleotide variants, splicing defects, promoter mutations, whole-gene deletions, and tandem copy-number duplications affecting the genes encoding cytochrome P450 2D6 (CYP2D6 on chromosome 22q13.2) and cytochrome P450 2C19 (CYP2C19 on chromosome 10q23.33). Together, these two microsomal heme-thiolate monooxygenases catalyze the oxidative Phase I pharmacokinetics of approximately 35% to 40% of commonly prescribed medications—despite CYP2D6 representing only 2% to 4% and CYP2C19 representing only 1% to 2% of total hepatic cytochrome P450 protein content.

Because neither CYP2D6 (which is non-inducible by nuclear receptors such as PXR or CAR) nor CYP2C19 exhibits uniform activity across human populations, inherited star-allele diplotypes produce 10- to 100-fold inter-individual differences in metabolic clearance and prodrug bioactivation. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines use CYP2D6 and CYP2C19 genotypes to guide dosing and drug selection for opioid analgesics, tamoxifen, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), the antiplatelet agent clopidogrel, proton pump inhibitors (PPIs), and triazole antifungals.

The Chromosome 22q13.2 CYP2D Gene Cluster and Star Alleles

The human CYP2D6 gene (9 exons spanning ~4.4 kb on chromosome 22q13.2) resides at the 3' end of a tandem evolutionary gene cluster downstream of two non-functional pseudogenes, CYP2D7 (inactivated by a frameshift insertion in exon 1) and CYP2D8. Because CYP2D6 and CYP2D7 share 94% sequence identity and are flanked by highly homologous 2.8-kb repeat elements (REP6 and REP7) containing Alu retrotransposons, misaligned sister chromatids or homologous chromosomes frequently undergo unequal meiotic crossover and gene conversion. This genomic instability has generated over 160 curated PharmVar star alleles spanning four functional categories:

• No-Function (Loss-of-Function) Alleles (Activity Value = 0):
• *CYP2D6\*3* (c.2549delA): Single-nucleotide frameshift deletion in exon 5 causing premature termination.
• *CYP2D6\*4* (c.1846G>A): Canonical splice-acceptor defect at the intron 3 / exon 4 junction that shifts the reading frame by one base, accounting for ~70% to 75% of all non-functional alleles in European populations (allele frequency ~18–20%).
• *CYP2D6\*5*: Whole-gene deletion of the entire CYP2D6 coding locus produced by unequal crossover between flanking REP sequences (allele frequency ~3–6% globally).
• *CYP2D6\*6* (c.1707delT): Exon 3 frameshift deletion.
• Hybrid Tandem Rearrangements (*\*13*, *\*36*, *\*68*): Non-functional chimeric CYP2D6–CYP2D7 fusion genes created by unequal recombination.
• Decreased-Function Alleles (Activity Value = 0.25 or 0.5):
• *CYP2D6\*10* (c.100C>T, p.Pro34Ser; Activity Value = 0.25): Disrupts the N-terminal proline-rich PPGP motif required for nascent microsomal folding, causing thermal instability and reduced heme incorporation. *\*10* is the most common allele in East Asian populations (allele frequency ~40–50%).
• *CYP2D6\*17* (c.1023C>T p.Thr107Ile + c.2850C>T p.Arg296Cys; Activity Value = 0.5): Alters active-site substrate recognition; prevalent in Sub-Saharan African populations (~15–25%).
• *CYP2D6\*29* (Activity Value = 0.5) and *CYP2D6\*41* (c.2988G>A intron 6 splicing defect Reducing full-length mRNA expression; Activity Value = 0.5).
• Normal-Function Alleles (Activity Value = 1.0): *CYP2D6\*1* (reference wild-type) and *CYP2D6\*2* (p.Arg296Cys + p.Ser486Thr).
• Increased-Function Gene Duplications (Activity Value = 1.0 × N): Tandem duplications or multiplications of functional alleles (*CYP2D6\*1xN* or *\*2xN*, where N ranges from 2 to 13 copies), conferring Ultrarapid Metabolizer status in 1–2% of Northern Europeans, 7–10% of Mediterranean Europeans, and 20–29% of Northeast African (Ethiopian) and Middle Eastern populations.

In the unified CPIC/DPWG consensus system, summing the maternal and paternal allele values yields the Activity Score (AS): AS = 0 defines a Poor Metabolizer (PM); AS = 0.25 to 1.0 defines an Intermediate Metabolizer (IM); AS = 1.25 to 2.25 defines a Normal Metabolizer (NM); and AS > 2.25 defines an Ultrarapid Metabolizer (UM).

Clinical Actionability of CYP2D6: Opioids, Tamoxifen, and Psychotropics

1. Opioid Prodrugs (Codeine and Tramadol): Codeine is an inactive analgesic prodrug; approximately 5% to 10% of an oral dose undergoes CYP2D6-catalyzed O-demethylation to morphine, which binds μ-opioid receptors with 200-fold higher affinity than codeine. Similarly, CYP2D6 O-demethylates tramadol into its active opioid metabolite (+)-O-desmethyltramadol (M1). In CYP2D6 Poor Metabolizers (AS = 0), morphine or M1 formation is negligible, resulting in complete lack of analgesia. Conversely, in Ultrarapid Metabolizers (AS > 2.25), standard doses of codeine or tramadol are rapidly converted into toxic systemic concentrations of morphine or M1, causing life-threatening or fatal respiratory depression—particularly in pediatric patients after tonsillectomy and in breastfed neonates of UM mothers. CPIC recommends avoiding codeine and tramadol in both PMs and UMs, substituting non-CYP2D6 analgesics (such as morphine, hydromorphone, or NSAIDs).
2. Tamoxifen in Estrogen-Receptor-Positive Breast Cancer: Tamoxifen is a selective estrogen receptor modulator (SERM) prodrug that requires sequential oxidation by CYP3A4/5 (N-demethylation) and CYP2D6 (4-hydroxylation) to form 4-hydroxytamoxifen and endoxifen (4-hydroxy-N-desmethyltamoxifen), which possess ~100-fold greater affinity for estrogen receptor alpha (ERα) than parent tamoxifen. CYP2D6 PMs and IMs generate markedly lower plasma endoxifen trough concentrations (<14–16 nM) and face higher rates of breast cancer recurrence; CPIC guidelines recommend switching postmenopausal PM/IM patients to an aromatase inhibitor (such as anastrozole or letrozole) or escalating tamoxifen to 40 mg/day in IMs if aromatase inhibitors are contraindicated.
3. Antidepressants, Atomoxetine, Ondansetron, and Eliglustat: CYP2D6 clears tricyclic antidepressants (amitriptyline, nortriptyline, desipramine, imipramine), the SSRIs paroxetine and fluvoxamine, the ADHD medication atomoxetine, the 5-HT₃ antiemetic ondansetron (where UMs experience antiemetic failure due to rapid clearance), and the glucosylceramide synthase inhibitor eliglustat used in Gaucher disease type 1 (which requires FDA-mandated pre-treatment CYP2D6 genotyping).

Loss-of-Function (*\*2*, *\*3*) and Promoter Gain-of-Function (*\*17*) Alleles

The CYP2C19 gene (9 exons on chromosome 10q23.33, clustered alongside CYP2C8, CYP2C9, and CYP2C18) exhibits three primary clinical alleles that define five metabolizer phenotypes:

• *CYP2C19\*2* (c.681G>A, rs4244285): A synonymous-appearing transition in exon 5 that activates an aberrant cryptic splice donor site 40 base pairs upstream of the canonical intron 5 junction, deleting 40 nucleotides from the mRNA transcript and introducing a premature stop codon that truncates the heme-binding domain (0% enzyme activity). The *\*2* allele frequency is ~15% in Europeans and Africans, ~29–35% in East and South Asians, and >50% in Indigenous Oceanian populations.
• *CYP2C19\*3* (c.636G>A, p.Trp212Ter, rs4986893): A nonsense mutation in exon 4 creating a premature stop codon (0% activity), occurring at ~2–9% frequency in East Asians and Pacific Islanders but <0.5% in Europeans.
• *CYP2C19\*17* (c.-806C>T, rs12248560): A gain-of-function single-nucleotide variant in the 5'-flanking promoter region that creates a consensus binding site for hepatic GATA transcription factors, increasing CYP2C19 gene transcription and catalytic capacity. Individuals with *\*1/\*17* are classified as Rapid Metabolizers (RM), and *\*17/\*17* homozygotes are Ultrarapid Metabolizers (UM).

Clopidogrel Antiplatelet Therapy, PPIs, Voriconazole, and SSRIs

1. Clopidogrel: Clopidogrel is an oral thienopyridine antiplatelet prodrug used after acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI) to prevent stent thrombosis. Approximately 85% of absorbed clopidogrel is inactivated by hepatic carboxylesterase 1 (CES1), while the remaining 15% requires a sequential two-step oxidative bioactivation—converting clopidogrel to 2-oxo-clopidogrel and then to the active thiol metabolite (H4), which irreversibly forms a disulfide bridge with Cys97 on the platelet P2Y₁₂ ADP receptor. CYP2C19 contributes ~45% of the first oxidative step and ~20% of the second step. Patients carrying one or two CYP2C19 loss-of-function alleles (*\*2* or *\*3*, IMs and PMs) generate 30% to 70% less active thiol metabolite, exhibit high on-treatment platelet reactivity, and suffer significantly higher rates of myocardial infarction, stroke, and stent thrombosis. Supported by an FDA Boxed Warning and randomized trials (TAILOR-PCI and POPular Genetics), CPIC recommends replacing clopidogrel with prasugrel or ticagrelor (which do not depend on CYP2C19 for bioactivation) in CYP2C19 IM and PM patients undergoing PCI or neurovascular stenting.
2. Proton Pump Inhibitors (PPIs): First-generation PPIs (omeprazole, lansoprazole, pantoprazole, dexlansoprazole) are cleared predominantly (~80%) by CYP2C19. In CYP2C19 RMs (*\*1/\*17*) and UMs (*\*17/\*17*), rapid hepatic clearance lowers intragastric pH control and causes Helicobacter pylori eradication failure or refractory erosive esophagitis at standard doses, prompting CPIC to recommend doubling the daily PPI dose (or using rabeprazole/vonoprazan).
3. Voriconazole and SSRIs: The antifungal voriconazole displays nonlinear saturable CYP2C19 pharmacokinetics; RMs/UMs fail to achieve therapeutic troughs (risking invasive Aspergillus mortality), whereas PMs experience neurotoxicity (visual hallucinations) and hepatotoxicity. For the SSRIs citalopram and escitalopram, CYP2C19 PMs accumulate high plasma concentrations that prolong the cardiac QTc interval via hERG potassium channel blockade, requiring a 50% reduction in maximum daily dose (capping citalopram at 20 mg/day and escitalopram at 10 mg/day).

Why is CYP2D6 considered non-inducible whereas CYP2C19 can be induced?

Unlike CYP3A4, CYP2C9, and CYP2C19—whose 5' promoter regions contain xenobiotic response elements bound by the pregnane X receptor (PXR), constitutive androstane receptor (CAR), and glucocorticoid receptor (inducing transcription upon exposure to rifampin, phenobarbital, or St. John's wort)—the CYP2D6 promoter lacks functional PXR/CAR binding motifs. Consequently, inter-individual variation in baseline CYP2D6 activity is governed predominantly by inherited germline copy-number and sequence variants rather than enzymatic induction.

Why is a *CYP2C19\*2/\*17* compound heterozygote classified as an Intermediate Metabolizer rather than a Normal Metabolizer?

In a *CYP2C19\*2/\*17* diplotype, one chromosome carries the complete loss-of-function splice defect (*\*2*, 0% activity) while the homologous chromosome carries the promoter gain-of-function variant (*\*17*). Pharmacokinetic studies with clopidogrel and escitalopram demonstrate that the moderate transcriptional increase from a single *\*17* allele cannot fully compensate for the complete loss of enzyme production from the *\*2* allele. Therefore, CPIC classifies *\*2/\*17* patients as Intermediate Metabolizers (IM) and recommends alternative antiplatelet therapy (prasugrel or ticagrelor) following PCI.

How do strong CYP2D6 inhibitors like fluoxetine and paroxetine cause phenoconversion?

Fluoxetine (and its long-lived metabolite norfluoxetine) and paroxetine act as mechanism-based or high-affinity competitive inhibitors of CYP2D6 (K_i in the nanomolar range). When co-administered to a genotypic CYP2D6 Normal Metabolizer (*\*1/\*1*), they occupy or inactivate >85–90% of hepatic CYP2D6 active sites, converting the patient into a functional Poor Metabolizer. In breast cancer patients taking tamoxifen, co-prescribing paroxetine or fluoxetine suppresses plasma endoxifen levels to PM levels; weak CYP2D6 inhibitors such as venlafaxine, citalopram, or escitalopram should be used instead.

1. Crews, K. R., Monte, A. A., Huddart, R., Caudle, K. E., Kharasch, E. D., Gaedigk, A., et al. (2021). "Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy." Clinical Pharmacology & Therapeutics, 110(4), 888–896. https://doi.org/10.1002/cpt.2149
2. Lee, C. R., Luzum, J. A., Sangkuhl, K., Gammal, R. S., Sabatine, M. S., Stein, C. M., et al. (2022). "Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update." Clinical Pharmacology & Therapeutics, 112(5), 959–967. https://doi.org/10.1002/cpt.2526
3. Caudle, K. E., Sangkuhl, K., Whirl-Carrillo, M., Swen, J. J., Haidar, C. E., Klein, T. E., et al. (2020). "Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group." Clinical and Translational Science, 13(1), 116–124. https://doi.org/10.1111/cts.12692
4. Goetz, M. P., Sangkuhl, K., Guchelaar, H. J., Schwab, M., Province, M., Whirl-Carrillo, M., et al. (2018). "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy." Clinical Pharmacology & Therapeutics, 103(5), 770–777. https://doi.org/10.1002/cpt.1007